NCT04535947View on ClinicalTrials.gov

Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)

PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

August 14, 2020

Primary Completion Date

February 10, 2021

Study Completion Date

February 10, 2021

Conditions
Dry Eye
Interventions
DRUG

Vehicle

Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.

DRUG

SDP-4 Ophthalmic Solution (1.0%)

Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.

Trial Locations (5)

38119

Total Eye Care, Memphis

63131

Ophthalmology Associates, St Louis

92562

LoBue Laser and Eye Medical Center, Murrieta

92663

Eye Research Foundation, Newport Beach

92843

Orange County Ophthalmology Medical Group, Garden Grove

All Listed Sponsors
lead

Silk Technologies, Ltd.

INDUSTRY

NCT04535947 - Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202) | Biotech Hunter | Biotech Hunter